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Vascular endothelial growth factor is an important angiogenic factor for tumour progression because it increases endothelial-
cell proliferation and remodels extracellular matrix in blood vessels. We demonstrated that hyperthermia at 428C, termed
heat shock, suppressed the gene expression and production of vascular endothelial growth factor in human ﬁbrosarcoma HT-
1080 cells and inhibited its in vitro angiogenic action on human umbilical vein endothelial cells. The gene expression of
alternative splicing variants for vascular endothelial growth factor, VEGF121, VEGF165 and VEGF189, was constitutively detected
in HT-1080 cells, but the VEGF189 transcript was less abundant than VEGF121 and VEGF165. When HT-1080 cells were
treated with heat shock at 428C for 4 h and then maintained at 378C for another 24 h, the gene expression of all vascular
endothelial growth factor variants was suppressed. In addition, HT-1080 cells were found to produce abundant VEGF165, but
much less VEGF121, both of which were inhibited by heat shock. Furthermore, the level of vascular endothelial growth factor
in sera from six cancer patients was signiﬁcantly diminished 2–3 weeks after completion of whole-body hyperthermia at 428C
(49.9+36.5 pg ml
71, P50.01) as compared with that prior to the treatment (177.0+77.5 pg ml
71). On the other hand,
HT-1080 cell-conditioned medium showed vascular endothelial growth factor-dependent cell proliferative activity and the
augmentation of pro-matrix metalloproteinase-1 production in human umbilical vein endothelial cells. The augmentation of
endothelial-cell proliferation and pro-matrix metalloproteinase-1 production was poor when human umbilical vein endothelial
cells were treated with conditioned medium from heat-shocked HT-1080 cells. These results suggest that hyperthermia acts as
an anti-angiogenic strategy by suppressing the expression of tumour-derived vascular endothelial growth factor production and
thereby inhibiting endothelial-cell proliferation and extracellular matrix remodelling in blood vessels.
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Angiogenesis is essential for tumour development and metastasis,
and tumour-derived angiogenic factor(s) play(s) an important role
in the formation of new vessels and tumour progression in vivo
and in vitro (Weidner et al, 1991; Ferrara et al, 1992; Folkman,
1992). Vascular endothelial growth factor (VEGF) (Ferrara and
Henzel, 1989; Leung et al, 1989), basic ﬁbroblast growth factor
(bFGF) (Abraham et al, 1986; Gospodarowicz et al, 1987), trans-
forming growth factor-a (TGF-a) (Schreiber et al, 1986) and
platelet-derived growth factor (Holmgren et al, 1991; Risau et al,
1992) all have been identiﬁed as angiogenic factors. Among them,
VEGF is considered to be the pivotal factor in tumour neovascular-
isation, because it increases in endothelial-cell proliferation and
migration (Leung et al, 1989; Connolly et al, 1989; Ferrara et al,
1992), enhancement of tumour growth in vivo (Kondo et al,
1993, 2000) and remodelling of perivascular matrices by augment-
ing proteinases such as matrix metalloproteinases (MMPs) (Fisher
et al, 1994; Moses, 1997).
VEGF is a 34–42 kDa heparin-binding and dimeric glycopro-
tein, and four isoforms have been characterised. Three of these,
VEGF121, VEGF165 and VEGF189 are composed of 121, 165 and
189 amino acids, respectively, and are generated by alternative spli-
cing of eight exons (Tischer et al, 1991). VEGF189 is encoded by all
the exons, and VEGF165 and VEGF121 are missing the amino acid
residues corresponding to exon 6 and exons 6 and 7, respectively
(Tischer et al, 1991). The fourth VEGF cDNA species, VEGF206
was discovered in a human foetal-liver cDNA library and the gene
codes for a predicted protein with 206 amino acids. In comparison
to VEGF165, VEGF206 contains an additional 41 amino acids
between exons 5 and 7 as well as a basic 24 amino acid insertion
also found in VEGF189 (Houck et al, 1991). VEGF165 and VEGF121
have been reported to be secreted in a wide variety of transformed
cell lines (Senger et al, 1986; Connolly et al, 1989; Myoken et al,
1991; Kondo et al, 1994) and VEGF165 is an abundant species
detectable in several tumours (Ferrara et al, 1992). In contrast,
VEGF189 and VEGF206 exist on the cell surface as structural proﬁles
possessing hydrophobic residues (Houck et al, 1991). On the other
hand, several therapeutic studies show that the inhibition of the
biological activity and/or the production of VEGF suppresses
tumour angiogenesis and growth in vivo (Kim et al, 1993; Kondo
et al, 1993; Asano et al, 1995; Borgstrom et al, 1996; Cheng et
al, 1996; Saleh et al, 1996; Im et al, 1999), suggesting that
tumour-derived VEGF plays a crucial role for tumour neovascular-
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www.bjcancer.comisation in vivo. Therefore, the suppression of VEGF expression in
tumours would become a potent clinical strategy in cancer therapy
for regulating tumour angiogenesis.
Hyperthermic treatment of malignant tumours is one cancer
therapy by which the possible mechanism of the proliferation of
tumour cells is relatively inhibited (Urano et al, 1983; Cellier et
al, 1993). In addition, Toyota et al (1997) reported that a whole-
body hyperthermia inhibits metastasis of breast cancer cells in rat
in vivo. Moreover, it has been reported that not only progression
but also metastasis of tumours are inhibited in most cases of cancer
patients treated with a whole-body hyperthermia (Takeuchi et al,
1996, 1999). We recently reported that heat shock suppresses in
vitro invasive activity of human ﬁbrosarcoma HT-1080 cells by
suppressing the production of membrane type 1-MMP (MT1-
MMP) and the activation of proMMP-2/progelatinase A (Sato et
al, 1999; Sawaji et al, 2000). On the other hand, Fajardo et al
(1988) reported that hyperthermia inhibits angiogenesis in vivo.
Therefore, it is likely that hyperthermia is efﬁcacious for preventing
tumour metastasis and invasion, but it remains unclear whether
hyperthermia could inﬂuence the expression of VEGF in tumour
cells.
In the present study, we investigated the effect of heat shock on
the production of VEGF in HT-1080 cells and the biological activ-
ities of conditioned medium from heat-shocked HT-1080 cells for
endothelial-cell proliferation and proMMP-1/interstitial procolla-
genase production. Heat shock suppressed the constitutively
expressed gene and the production of alternative splicing variants
of VEGF in HT-1080 cells. Similar suppression of VEGF level
was observed in vivo when patients with different cancers were
treated with the whole-body hyperthermia. In addition, the
augmentation of endothelial-cell proliferation and proMMP-1
production was reduced in the conditioned medium from heat-
shocked HT-1080 cells. Therefore, we suggest that hyperthermia
suppresses angiogenesis by inhibiting the production of tumour-
derived VEGF in vivo and in vitro.
MATERIALS AND METHODS
Cell culture and heat-shock treatment
Human ﬁbrosarcoma HT-1080 cells (Health Science Research
Bank, Osaka, Japan) were cultured in MEM (Life Technologies,
Inc., Grand Island, NY, USA) supplemented with 10% FBS (Asahi
Techno Glass Co., Tokyo, Japan) and MEM non-essential amino
acids (Life Technologies). Human umbilical vein endothelial cells
(HUVECs) (Takara Shuzo Co., Shiga, Japan) were cultured in
EBM supplemented with 2% FBS, 10 ng ml
71 human epidermal
growth factor and 12 mgm l
71 bovine brain extract (Takara
Shuzo). In the heat-shock experiments, conﬂuent HT-1080 cells
were treated with heat shock at 428C for 4 h in MEM supplemen-
ted with 0.2% lactalbumin hydrolysate and then incubated for
another 24 h at 378C (Sato et al, 1999; Sawaji et al, 2000). The
harvested culture medium was used for assay of endothelial-cell
proliferation and Western blot analysis as described below.
Semiquantiﬁcation of VEGF mRNA by reverse
transcriptase-polymerase chain reaction (RT–PCR)
Cytoplasmic RNA in untreated and heat-shocked HT-1080 cells was
isolated by ISOGEN (Nippon Gene Co., Toyama, Japan) according
to the manufacturer’s instructions. One microgram of the isolated
RNA was subjected to the synthesis of ﬁrst-strand cDNA by Molo-
ney-murine leukaemia virus reverse transcriptase, RNase inhibitor
(Roche Diagnostics, Tokyo, Japan) and oligo(dT)12–18 primer (Life
Technologies)for1 hat378C.One-tenthofthecDNAgeneratedfrom
the RT reaction was used for PCRampliﬁcation for human VEGFand
human glyceraldehyde-3-phosphate dehydrogenase (GAPDH). To
detect the individual splicing variants for VEGF, a common forward
primer and variant-speciﬁc reverse primers were designed (Table 1).
The forward and reverse primers for human GAPDH were 5'-
CCACCCATGGCAATTCCATGGCA-3' and 5'-TCTAGACGGCAG-
GTCAGGTCCACC-3', respectively. Polymerase chain reaction
(PCR) was performed with 928C for 40 s, at 548C for 40 s and 728C
for 1 min with 25–29 cycles for VEGFs and GAPDH. The ampliﬁed
PCRproducts were analysed on 1% agarose geland visualised by ethi-
dium bromide staining. The PCR products were subcloned into
pGEM-T vector (Promega, Madison, WI, USA), and then the cDNA
sequence was conﬁrmed with a Sequenase version 2.0 DNA sequen-
cing kit (Amersham Biosciences, Tokyo, Japan) according to the
manufacturer’s instructions. The relative amounts of the ampliﬁed
gene for VEGFs were quantiﬁed by densitometric scanning using
the Image Analyzer LAS-1000 plus (Fuji Photo Film Co., Ltd., Tokyo,
Japan) and then indicated after correction for that of GAPDH.
Western blot analysis for VEGF and proMMP-1
The production of VEGF in HT-1080 cells, and that of proMMP-1
in HUVECs were monitored by Western blot analysis with antibo-
dies against human VEGF and human proMMP-1, respectively.
Brieﬂy, the harvested culture medium was subjected to SDS–PAGE
with 12.5% and 10% acrylamide gel to detect VEGF and proMMP-
1, respectively, and then proteins separated in the gel were electro-
transferred onto a nitrocellulose membrane as described previously
(Takahashi et al, 1991). The membrane was reacted with rabbit
anti-(human VEGF) antibody (IBL, Gunma, Japan) or sheep
anti-(human proMMP-1) antibody (kindly provided by Dr Hideaki
Nagase), which was then complexed with horseradish peroxidase-
conjugated goat anti-(rabbit IgG)IgG or goat anti-(sheep IgG)IgG
(Sigma Chemical Co., St. Louis, MO, USA), respectively. Immu-
noreactive VEGF and proMMP-1 were visualised with ECL-
Western blotting detection reagents (Amersham Biosciences)
according to the manufacturer’s instructions. The relative amounts
of VEGF and proMMP-1 were quantiﬁed by densitometric scan-
ning using the Image Analyzer LAS-1000 plus (Fuji Photo Film).
Endothelial-cell proliferation assay
HUVECs (500 cells well
71) were seeded into 96-multi well plates
and cultured for 24 h at 378C to achieve cell adhesion. The cells
were washed twice with Ca
2+- and Mg
2+-free phosphate buffered
saline (PBS) and then incubated for the indicated periods with
the HT-1080 cell-conditioned medium which was diluted 1:1
(vol:vol) with 0.5% FBS/EBM. The proliferation of HUVECs was
monitored by alamer Blue assay (Wako Pure Chemical Co., Osaka,
Japan) (Ahmed et al, 1994) according to the manufacturer’s
instructions. The ﬂuorescence was measured by excitation at
540 nm and emission at 590 nm.
Neutralizing experiment with antibodies
The HT-1080 cell-conditioned medium was incubated ﬁrst with
50 mgm l
71 of polyclonal antibody against human VEGF, human
TGF-a, human tumour necrosis factor-a (TNF-a) (R&D Systems
Inc., Minneapolis, MN, USA) or monoclonal antibody against
human bFGF (Transduction Laboratories, Lexington, KY, USA) at
48C for 24 h and then incubated with Protein A-Sepharose (Amer-
sham Biosciences) for 1 h at room temperature. The Protein A-
Sepharose-IgG complex was precipitated by centrifugation at
100006g for 10 min and the resultant supernatant was sterilised
and then used for the assay of endothelial-cell proliferation and
proMMP-1 production as described above.
Whole-body hyperthermia
Whole-body hyperthermia was performed with a far-infrared radia-
tion heat device, using the instruments RHD2002 and RHS7500
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(Robins et al, 1985). Patients were anaesthetised and then subjected
to the hyperthermia by maintaining a temperature of 42–438C
locally in the hyperthermic chamber and 41.5–428C systemically
(rectal temperature) for 1 h (Takeuchi et al, 1996). The hyperther-
mic therapy was performed once a week for 4 weeks. Two–seven
days prior to the ﬁrst treatment, and 2–3 weeks after the comple-
tion of the whole-body hyperthermia, blood was collected from the
patients and then the serum level of VEGF was measured by VEGF
immunoassay. This therapeutic treatment was performed only after
approval of the protocol by the ethics committee of the hospital
and after obtaining informed consent.
Measurement of VEGF
The levels of VEGF in sera from six cancer patients before and after
whole-body hyperthermia were measured by human VEGF Immu-
noassay kit (R&D Systems) according to the manufacturer’s
instructions. A VEGF antibody contained in this kit recognises
both VEGF121 and VEGF165, and thus the immunoassay can be
used to determine mass values for human VEGF121 and VEGF165.
Statistical analysis
Data were analysed by Student’s t-test. P50.01 was considered to
be statistically signiﬁcant.
RESULTS
Gene expression of VEGF variants in HT-1080 cells
The VEGF gene consists of the common exons 1–5 and the indivi-
dually speciﬁc exons for the variants: exon 8 for VEGF121, exons 7
and 8 for VEGF165, and exons 6, 7 and 8 for VEGF189 (Figure 1).
A common forward primer for VEGF (v-F) (17–40 bp, exon 1)
was designed downstream from the start codon (Table 1 and Figure
1). Speciﬁc reverse primers for VEGF121 (v121-R), VEGF165 (v165-
R) and VEGF189 (v189-R) were also designed across exons 5 and 8
(418–441 bp), exons 5 and 7 (418–441 bp) and exons 6 and 7
(481–504 bp), respectively (Table 1 and Figure 1). We ﬁrst charac-
terised the expression of VEGF transcripts in HT-1080 cells by RT–
PCR analysis using these PCR primers. As shown in Figure 2, the
gene expression of VEGF121 (425 bp), VEGF165 (425 bp) and
VEGF189 (488 bp) was detected in HT-1080 cells and the ampliﬁca-
tion was cycle number-dependent. In addition, the gene level of
VEGF189 was found to be less than that of VEGF121 and VEGF165
in HT-1080 cells. Furthermore, we conﬁrmed that the DNA
sequence of the ampliﬁed VEGF variants was completely identical
to that in the previous paper by Leung et al (1989) (data not
shown). However, we did not detect a VEGF206 transcript in HT-
1080 cells by RT–PCR using the common forward primer and a
speciﬁc reverse one that was designed with a terminal codon in exon
8 (data not shown).
Heat shock suppresses gene expression and production of
VEGF in HT-1080 cells
We examined the inﬂuence of heat shock on the gene expression of
VEGF variants in HT-1080 cells. When the cells were pretreated with
heat shock at 428C for 4 h and then incubated for another 24 h at
378C, VEGF121, VEGF165 and VEGF189 transcripts were decreased
to 34, 45 and 41%, respectively, of the values for the untreated cells
(Figure 3). Western blot analysis showed that HT-1080 cells
produced abundant VEGF165 with the same mobility of recombi-
nant human VEGF165 (Figure 4, lane 1). The production of
VEGF165 in heat-shocked HT-1080 cells was suppressed to 53% of
the values for untreated cells (Figure 4, lane 2). In addition, VEGF121
was detected in HT-1080 cells, but in a much smaller amount than
VEGF165, and its production was similarly suppressed by heat shock
(Figure 4, lanes 1 and 2). Therefore, these results suggest that heat
shock suppresses the production of VEGF165 and VEGF121 through
the depression of their mRNA expression in HT-1080 cells.
Effect of conditioned medium from heat-shocked HT-1080
cells on proliferation of HUVECs
VEGF possesses the mitogenic activity to cause proliferation of
endothelial cells in angiogenesis (Leung et al, 1989; Connolly et
al, 1989; Ferrara et al, 1992). We next examined the endothelial-cell
proliferative activity of conditioned medium from untreated and
heat-shocked HT-1080 cells. When the conditioned medium from
HT-1080 cells was added to HUVECs, the endothelial-cell prolif-
eration was increased in a time-dependent manner and doubled
for 3 days (Figure 5, ﬁlled triangles). However, the conditioned
medium from heat-shocked HT-1080 cells no longer indicated
proliferative activity toward HUVECs (Figure 5, ﬁlled squares).
On the other hand, as shown in Figure 6, the enhancement of
endothelial-cell proliferation by the conditioned medium from
HT-1080 cells (lane 2) was neutralised with an antibody against
VEGF (lane 3), but not by an antibody to bFGF (lane 4), which
is known as another angiogenic factor in vivo and in vitro (Abra-
ham et al, 1986; Gospodarowicz et al, 1987). In addition, we
conﬁrmed that neither TGF-a nor TNF-a antibody interfered with
the proliferative activity on HUVECs (data not shown). These
results indicate that the enhancement of endothelial-cell prolifera-
tion by conditioned medium from HT-1080 cells was mediated
speciﬁcally by VEGF, and suggest that heat shock is adequate for
inhibiting the endothelial-cell proliferation by suppressing
tumour-derived VEGF production.
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Table 1 PCR primer sets for ampliﬁcation of human VEGF splicing variants
Forward Reverse
Gene Primer Sequence (location) Primers Sequence (location) Product size
VEGF121 v121-R 5'-CCGCCTCGGCTTGTCACATTTTTC-3' (418–441 bp) 425 bp
VEGF165 v-F 5'-CTTGGGTGCATTGGAGCCTTGCCT-3' v165-R 5'-TGAGCAAGGCCCACAGGGATTTTC-3' (418–441 bp) 425 bp
VEGF189 (17–40 bp) v189-R 5'-CCCACAGGGAACGCTCCAGGACTT-3' (481–504 bp) 488 bp
1-5
1-5
1-5
VEGF121
VEGF165
VEGF189
v121-R
v165-R
v189-R
v-F
v-F
v-F
8
8
8
7
7 6
Figure 1 Structure of human VEGF mRNA. Exons are represented by
box and numbered. Arrows indicate the speciﬁc primers for VEGF variants
as shown in Table 1.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(10), 1597–1603Effect of conditioned medium from heat-shocked HT-1080
cells on production of endothelial proMMP-1
The augmentation of proteolytic activity is crucial for extracellular
matrix (ECM) remodelling in order to provide a permissive envir-
onment in which activated endothelial cells can proliferate and
form new vessels (Moses, 1997; Liotta et al, 1991). In addition,
endothelial MMPs such as MMP-1 and MT1-MMP have been
shown to participate in ECM remodelling in the perivascular envir-
onment (Fisher et al, 1994; Hiraoka et al, 1998). We therefore
investigated the effect of conditioned medium from HT-1080 cells
on the production of proMMP-1 in HUVECs. Western blot analy-
sis showed that the production of proMMP-1 in HUVEC was
augmented by the conditioned medium from HT-1080 cells (6.2-
fold) as well as by recombinant human VEGF165 (4.2-fold) (Figure
7A, lanes 2 and 4, respectively). In addition, the augmentation of
proMMP-1 production was inhibited by adding a neutralising anti-
body against VEGF (Figure 7A, lanes 3 and 5). Furthermore, the
augmentation of proMMP-1 production was poor in HUVECs
treated with the conditioned medium from heat-shocked HT-
1080 cells rather than that from untreated HT-1080 cells (Figure
7B, lanes 2 and 3). These results suggest that heat shock is efﬁca-
cious in the prevention of MMP-dependent ECM remodelling in
the process of angiogenesis by suppressing the production of
tumour-derived VEGF.
Whole-body hyperthermia diminishes the serum level of
VEGF in cancer patients in vivo
To clarify whether hyperthermia inhibits the production of VEGF
in vivo, we investigated the serum level of VEGF in various cancer
patients before and after whole-body hyperthermia at 428C (Takeu-
chi et al, 1996, 1999). The patient characteristics are listed in Table
2. Six patients had various forms of advanced cancer, and the
histology and tumour-node-metastasis (TNM) in the individual
patients were characterised at the initial diagnosis. In addition, ﬁve
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Figure 2 Characterisation of gene expression of VEGF splicing variants in
human ﬁbrosarcoma HT-1080 cells. Isolated RNA (1 mg) was subjected to
RT–PCR analysis with 25 (lanes 1, 4 and 7), 27 (lanes 2, 5 and 8) and 29
cycles (lanes 3, 6 and 9) using speciﬁc primers for respective VEGF splicing
variants; VEGF121, VEGF165 and VEGF189 as indicated in Figure 1 and Table
1. Two independent experiments were reproducible and typical data were
shown. Lanes 1–3, VEGF121; lanes 4–6, VEGF165 and lanes 7–9, VEGF189.
VEGF121 VEGF165 VEGF189
100       34           100        45           100       41
–          +              –          +              –           + 
: Relative amounts
VEGF mRNA
GAPDH mRNA
: Heat shock
Figure 3 Heat shock suppresses gene expression of VEGF variants in
HT-1080 cells. Conﬂuent HT-1080 cells were treated with or without heat
shock at 428C for 4 h and then incubated for another 24 h. Isolated RNA
was subjected to RT–PCR analysis with 27 cycles for VEGF121 and
VEGF165 and with 29 cycles for VEGF189 as described in Figure 2. The re-
lative amounts of VEGF mRNA were quantiﬁed by densitometric scanning
followed by normalising against that of GAPDH mRNA and expressed tak-
ing the untreated HT-1080 cells as 100. Three independent experiments
were reproducible and typical data were shown.
100           53    : Relative amounts
1                 2                3                4     
VEGF165
VEGF121
Figure 4 Heat shock suppresses production of VEGF in HT-1080 cells.
Conﬂuent HT-1080 cells were treated with or without heat shock as de-
scribed in Figure 3. The harvested culture medium was subjected to Wes-
tern blot analysis for VEGF as described in Materials and Methods. The
relative amounts of VEGF165 were quantiﬁed by densitometric scanning
and expressed taking the untreated HT-1080 cells as 100. Three indepen-
dent experiments were reproducible and typical data were shown. Lane 1,
untreated HT-1080 cells; lane 2, heat-shocked HT-1080 cells; lane 3, re-
combinant human VEGF165 (10 ng) and lane 4, recombinant human
VEGF121 (20 ng).
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Figure 5 Proliferation of HUVECs by HT-1080 cell-derived conditioned
medium. HUVECs (500 cells well
-1) were treated with control medium
(ﬁlled circles), with the HT-1080 cell-conditioned medium (ﬁlled triangles)
or with the heat-shocked HT-1080 cell-conditioned medium (ﬁlled
squares). The proliferation of HUVECs was monitored by alamer Blue assay
as described in Materials and Methods. The data are the mean+s.d. of va-
lues from six wells at each point. ***Signiﬁcantly different from HUVECs
treated with control medium (P50.001). Two independent experiments
were reproducible and typical data were shown.
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therapy. When sera from these patients were collected 2–7 days
prior to the ﬁrst whole-body hyperthermia, the serum level of
VEGF was higher than 100 pg ml
71 in all patients and its average
(+s.d) was 177.0 (+77.5) pg ml
71 (Table 2). Two–three weeks
after completion of the hyperthermic therapy, the level of VEGF
decreased to 49.9 (+36.5) pg ml
71, which was almost the same
as the normal VEGF level (Hyodo et al, 1998). Therefore, it is
suggested that whole-body hyperthermia efﬁciently diminishes the
level of VEGF in advanced cancer patients.
DISCUSSION
VEGF has been characterised as existing in four isoforms; VEGF121,
VEGF165, VEGF189 and VEGF206 (Ferrara et al, 1992). To individu-
ally and speciﬁcally amplify these variants by semi-quantitative
RT–PCR, we designed unique PCR primers and demonstrated that
HT-1080 cells expressed predominantly VEGF121 and VEGF165
mRNA as well as a smaller amount of the VEGF189 transcript,
and did not express VEGF206. In addition, Western blot analysis
showed that the immunoreactive VEGF was mostly VEGF165 and
a smaller amount of VEGF121, while the mRNA level of both
isoforms was the same in HT-1080 cells. No immunologically
detected VEGF variants could be found in the cell-membrane frac-
tion of HT-1080 cells (data not shown), although VEGF189 and
VEGF206 exist as cell-associated forms (Houck et al, 1991). On
the other hand, tumour cells have been shown to produce other
angiogenic factors such as bFGF (Abraham et al, 1986; Gospodar-
owicz et al, 1987), TGF-a (Smith et al, 1987) and PDGF
(Holmgren et al, 1991; Risau et al, 1992). We demonstrated that
the proliferation of HUVECs by conditioned medium derived from
HT-1080 cells was effectively prevented by adding VEGF antibody,
but not by adding antibodies to bFGF, TGF-a and TNF-a (data not
shown). Therefore, it is suggested that the angiogenic factor
derived from HT-1080 cells is primarily VEGF165.
Exposing malignant cells to hyperthermia is a therapeutic strat-
egy that prevents tumour progression by inhibiting the
proliferation of tumour cells (Urano et al, 1983). Fajardo et al
(1988) also reported that hyperthermia inhibits angiogenesis by
interference with cell replication and/or inhibition of the migration
of vascular endothelial cells. However, the effect of hyperthermia
on the production of VEGF is not speciﬁed. In the present study,
we demonstrated for the ﬁrst time that heat shock suppresses the
gene expression and the production of VEGF165 in HT-1080 cells.
Moreover, the heat shock-mediated suppressions of both VEGF165
production and its gene expression were similarly observed in
human squamous carcinoma A431 cells (data not shown). Thus,
this novel evidence that heat shock directly down-regulates the
expression of VEGFs in HT-1080 cells is likely to be ubiquitously
observed in tumour cells.
Endothelial cells are basically quiescent, but when activated by
VEGF, they turn into the angiogenic phenotype and then prolifer-
ate and migrate to form new vessels in vivo and in vitro (Weidner
et al, 1991; Ferrara et al, 1992). In addition, VEGF-mediated
neovascularisation is closely associated with tumour growth in vivo
(Kim et al, 1993; Asano et al, 1995; Cheng et al, 1996; Im et al,
1999). In fact, Kim et al (1993) reported that the intraperitoneal
injection of a speciﬁc monoclonal antibody for human VEGF165
inhibits the growth of rhabdomyosarcoma, glioblastoma multi-
forme and leiomyosarcoma cell lines in nude mice. Im et al
(1999) also reported that an antisense cDNA molecule of VEGF
induces anti-tumorigenic effects in vivo on human glioma tumours
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
s
20
15
10
5
0
F
l
u
o
r
e
s
c
e
n
t
 
i
n
t
e
n
s
i
t
y
 
(
´
 
1
0
3
)
1                       2                       3                       4
***
Figure 6 Characterisation of HT-1080 cell-derived factor for endothe-
lial-cell proliferation. Conditioned medium from HT-1080 cells was pre-
treated with an antibody against VEGF (50 mgm l
71) or bFGF
(50 mgm l
71) and then HUVECs (500 cells well
71) were treated with
or without the conditioned medium. After 2 days treatment, the prolif-
eration of HUVECs was monitored by alamer Blue assay as described in
Figure 5. The data are the mean+s.d. of values from six wells. Two in-
dependent experiments were reproducible and typical data were shown.
Lane 1, HUVECs cultured in control medium; lane 2, HUVECs treated
with the HT-1080 cell-conditioned medium; lane 3, HUVECs treated
with the HT-1080 cell-conditioned medium pretreated with VEGF anti-
body and lane 4, HUVECs treated with the HT-1080 cell-conditioned
medium pretreated with bFGF antibody. ***Signiﬁcantly different from
HUVECs treated with the HT-1080 cell-conditioned medium
(P50.001).
100          620            275          415          183 : Relative amounts
1              2               3               4               5
100          628          238     : Relative amounts
1              2              3
proMMP-1
proMMP-1
A
B
Figure 7 HT-1080 cell-derived VEGF stimulates HUVECs to produce
proMMP-1. (A) Conditioned medium from HT-1080 cells and the culture
medium supplemented with human recombinant VEGF165 (20 ng ml
71)
were pretreated with or without an antibody against VEGF (50 mgm l
71)
and then HUVECs were treated with these conditioned media for 24 h.
The harvested culture medium was subjected to Western blot analysis
for proMMP-1 as described in Materials and Methods. Lane 1, untreated
HUVECs; lane 2, HUVECs treated with the HT-1080 cell-conditioned
medium; lane 3, HUVECs treated with the HT-1080 cell-conditioned med-
ium pretreated with VEGF antibody; lane 4, HUVECs treated with recom-
binant human VEGF165 and lane 5, HUVECs treated with recombinant
human VEGF165 pretreated with VEGF antibody. (B) Conﬂuent HUVECs
were treated with or without conditioned medium from untreated or
heat-shocked HT-1080 cells. Three independent experiments were repro-
ducible and typical data were shown. Lane 1, untreated HUVECs; lane 2,
HUVECs treated with the HT-1080 cell-conditioned medium and lane 3,
HUVECs treated with the heat-shocked HT-1080 cell-conditioned med-
ium. The relative amounts of proMMP-1 production were quantiﬁed by
densitometric scanning and expressed taking the untreated HUVECs as
100.
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ical target molecule for cancer therapy. Thus, our ﬁnding that heat
shock inhibited VEGF expression in tumour cells strongly suggests
that hyperthermia might be one therapeutic strategy for preventing
angiogenesis together with known therapeutic properties such as
anti-tumorigenic activity in vivo.
Recently, Kanamori et al (1999) reported that hyperthermia
at 448C induces the expression of VEGF in SCC VII tumours
in C3H/He mice, by the mechanism that heat-mediated vascular
damage may attribute to hypoxia and thereafter tumour necro-
sis. This phenomenon is different from our ﬁnding, that heat
shock suppresses VEGF expression in tumour cells. In our
experiments, heat shock at 428C for 4 h does not inﬂuence
cellular functions such as biosynthesis of total proteins and
tumour cell growth in vitro (Sato et al, 1999; Sawaji et al,
2000). Thus, the discrepancy may be due to the difference of
experimental conditions such as temperature and heat-exposing
period. Furthermore, we demonstrated that the level of VEGF
in serum was diminished in all cancer patients treated with
whole-body hyperthermia. Therefore, it is very likely that the
in vitro ﬁndings in the present study reﬂect on the in vivo
effect of whole-body hyperthermia, and that the suppression
of tumour progression and metastasis by whole-body hyperther-
mia may partly contribute to the prevention of angiogenesis by
inhibiting VEGF production in vivo.
Extracellular matrix remodelling is required for endothelial–cell
proliferation and migration in the process of angiogenesis, and is
closely dependent on endothelial cell-derived proteinases such as
MMPs (Liotta et al, 1991; Moses, 1997). Endothelial MMP-1 has
been shown to participate in angiogenesis in vitro (Unemori et
al, 1992; Fisher et al, 1994). A recent study by Hiraoka et al
(1998) also reported that MT1-MMP in endothelial cells is
involved in neovessel formation in mice deﬁcient in both plasmi-
nogen activator and plasminogen. In this communication, we
indicated that HT-1080 cells produced a large amount of VEGF
by which the production of proMMP-1 in HUVECs was augmen-
ted, and also that heat shock effectively interfered with the
production of VEGF. Furthermore, we recently reported that heat
shock suppresses in vitro tumour invasive activity by suppressing
the production of MT1-MMP and thereafter inhibiting the activa-
tion of proMMP-2 in tumour cells (Sato et al, 1999; Sawaji et al,
2000). Therefore, it is suggested that hyperthermia elicits not only
an anti-angiogenic effect by inhibiting tumour-derived VEGF
production but also an anti-metastatic action by suppressing the
production and activation of proMMPs.
In conclusion, we demonstrated that heat shock suppresses the
gene expression of three VEGF splicing variants, VEGF121, VEGF165
and VEGF189, and decreases the predominant product of VEGF165
in HT-1080 cells. In addition, the heat shock-mediated suppression
of VEGF production results in the inhibition of tumour cell-
induced proliferation and MMP production in endothelial cells.
Furthermore, whole-body hyperthermia diminished the augmented
level of VEGF in serum from patients with advanced cancers in
vivo. Therefore, these results strongly suggest that this suppression
by hyperthermia of tumour cell-derived VEGF production may
explain, in part, the reason why hyperthermic therapy effectively
prevents tumor growth and metastasis in vivo.
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